A new prognostic classification for overall survival in asian patients with previously untreated metastatic renal cell carcinoma

Cancer Science

Volumn 103, Issue 9, 2012, Pages 1695-1700

  Shinohara, Nobuo ^a   Nonomura, Katsuya ^a   Abe, Takashige ^a   Maruyama, Satoru ^a   Kamai, Takao ^b   Takahashi, Masayuki ^c   Tatsugami, Katsunori ^d   Yokoi, Shigeaki ^e   Deguchi, Takashi ^e   Kanayama, Hiroomi ^c   Oba, Koji ^f   Naito, Seiji ^d  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b DOKKYO MEDICAL UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKUSHIMA   (Japan)

^d KYUSHU UNIVERSITY   (Japan)

^e GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; LACTATE DEHYDROGENASE; RECOMBINANT ALPHA INTERFERON;

ADULT; AGED; ANEMIA; ARTICLE; ASIAN; BONE METASTASIS; BOOTSTRAPPING; CANCER PROGNOSIS; CLASSIFICATION ALGORITHM; EXTERNAL VALIDITY; FEMALE; HUMAN; INTERNAL VALIDITY; KIDNEY CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; VALIDITY;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INTERFERON-ALPHA; KIDNEY NEOPLASMS; MALE; METASTASECTOMY; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; TREATMENT OUTCOME;

EID: 84865793303     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02351.x     Document Type: Article

References (16)

1. Motzer RJ, Bacik J, Murphy BA et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20: 289-96.
2. Hudes G, Carducci M, Choueiri T et al. NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy. J Natl Compr Canc Netw 2011; 9 (Suppl): S1-29.
3. Motzer RJ, Hutson TE, Tomczak P et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 3584-90.
4. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-81.
5. Tomita Y, Shinohara N, Yuasa T et al. Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma. Jpn J Clin Oncol 2010; 40: 1166-72.
6. Yuasa T, Tsuchya N, Urakami S et al. Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib. BJU Int 2012; 109: 1349-54.
7. Shinohara N, Abe T, Mochizuki T et al. Is Memorial Sloan-Kettering Cancer Center risk classification appropriate for Japanese patients with metastatic renal cell carcinoma in the cytokine era? Urol Oncol 2011; doi:10.1016/j.urolonc.2011.08.009 [Epub ahead of print].
8. Naito S, Yamamoto N, Takayama T et al. Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients. Eur Urol 2010; 57: 317-25.
9. Mekhail TM, Abou-Jawde RM, BouMerhi G et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005; 23: 832-41.
10. Negrier S, Escudier B, Gomez F et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie. Ann Oncol 2002; 13: 1460-8.
11. Sobin LH, Wittekind CH, eds. International Union Against Cancer (UICC). TNM Classification of Malignant Tumours, 5th edn. New York: John Wiley & Sons, Inc., 1997.
12. Japanese Urological Association, The Japanese Society of Pathology and Japanese Radiological Society. General Rules for Clinical and Pathological Studies on Renal Cell Carcinoma, 4th edn. Tokyo: Kanehara, 2011.
13. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361-87.
14. Efron B, Tibshirani R. An Introduction to the Bootstrap. New York: Chapman & Hall, 1993.
15. Miyake H, Kurahashi T, Takenaka T, Inoue T, Fujisawa F. Clinical outcome of combined immunotherapy with interferon-α and low-dose interleukin-2 for Japanese patients with metastatic renal cell carcinoma. Urol Oncol 2009; 27: 598-603.
16. Akaza H, Kawai K, Tsukamoto T et al. Successful outcomes using combination therapy of interleukin-2 and interferon-α for renal cell carcinoma patients with lung metastasis. Jpn J Clin Oncol 2010; 40: 684-9.